An interventional study of Sunflower Seed Supplementation in Hypercholesterolemia, sponsored by University of Faisalabad. Completed at 1 site in Pakistan. Open to male participants aged 40 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by University of Faisalabad · Not applicable, Interventional, and Treatment
This study evaluates the effect of daily consumption of sunflower seeds on blood cholesterol levels in adult participants. Participants were randomly assigned to consume a specified amount of sunflower seeds for a defined period, and their blood cholesterol and lipid profile were measured before and after the intervention. The study aims to determine whether sunflower seeds can contribute to improving cardiovascular health by lowering cholesterol. Adult men and women meeting the eligibility criteria were included in the study. The findings may help inform dietary recommendations for managing cholesterol and promoting heart health.
This randomized, open-label human trial evaluated the cholesterol-lowering potential of sunflower seeds in adult participants. Eligible men and women were recruited based on inclusion criteria, which included age range, baseline cholesterol levels, and absence of major health conditions. Participants were randomly assigned to consume a defined daily portion of sunflower seeds for a specified intervention period. Blood samples were collected at baseline and at the end of the intervention to measure total cholesterol, LDL-C, HDL-C, triglycerides, and other relevant lipid parameters.
Prior to the human intervention, sunflower seeds were analyzed for their nutritional composition, mineral content, phytochemical profile, and fatty acid composition using standard laboratory procedures. Tests included proximate analysis (moisture, protein, fat, ash, and carbohydrate content), mineral quantification (calcium, magnesium, potassium, etc.), phytochemical assays (total phenolics, flavonoids), and fatty acid profiling using gas chromatography. These analyses provided a detailed characterization of the seeds' bioactive components relevant to cardiovascular health.
The study also included assessments of dietary intake, anthropometric measurements, and adherence to the intervention. The primary objective was to determine the effect of sunflower seed consumption on blood cholesterol levels, while secondary objectives included evaluating changes in lipid profile and potential associations with bioactive components of the seeds. Data were analyzed using standard statistical methods. The results aim to provide evidence on the role of sunflower seeds in cardiovascular risk management and to inform dietary recommendations.
1,238 studies on the registry are indexed under Hypercholesterolemia; 109 are open to participants now.
This study's enrollment of 28 is below the median of 99 across 991 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →University of Faisalabad is the lead sponsor of 83 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants continued their usual diet without consuming sunflower seeds. Blood cholesterol and lipid profiles were measured at baseline and at the end of the study period.
Participants consumed a defined daily portion of sunflower seeds for the duration of the study. Blood samples were collected at baseline and after the intervention to measure total cholesterol, LDL-C, HDL-C, triglycerides, and other lipid parameters. Dietary intake and adherence to the intervention were monitored throughout the study period
Dietary Supplement: Sunflower Seed Supplementation
Participants consumed sunflower seeds daily for 45 days
Change in Total Cholesterol
Total serum cholesterol measured using standard enzymatic methods at baseline and at the end of the 45 days sunflower seed supplementation period.
Time frame: Baseline and 45 days after intervention
LDL Cholesterol
LDL cholesterol measured using standard enzymatic methods at baseline and at the end of the 45 days supplementation period.
Time frame: Baseline and 45 days after intervention
Plan to share: No — The study was completed prior to an IPD sharing plan, and participant consent did not include sharing of individual-level data.
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Faisalabad